Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- FDMT
- Price
- 4.79
- Stock movement up
- +0.44 (10.11%)
- Company name
- 4D Molecular Therapeutics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Markedsværdi
- 221.43M
- Ent værdi
- 84.97M
- Pris/omsætning
- 13025.33
- Pris/bog
- 0.40
- Udbytte afkast
- -
- Udbyttevækst
- -
- Vekst år
- -
- FCF-udbetaling
- -
- Efterfølgende P/E
- -
- Fremtidig P/E
- -
- PEG
- -
- EPS-vekst
- 31.97%
- 1 års afkast
- -82.44%
- 3 års afkast
- -13.81%
- 5 års afkast
- -
- 10 års afkast
- -
Senest opdateret: 2025-06-10
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UDBYTTE
FDMT betaler ikke udbytte
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VÆRDIANSÆTTELSE
Værdiansættelsesforhold
Loading...
Værdiansættelsesforhold-data
| Efterfølgende P/E | - |
| Pris til OCF | - |
| Pris til FCF | - |
| Pris til EBITDA | - |
| EV i forhold til EBITDA | - |
Værdiansættelse (salg/bogført værdi)
Loading...
Værdiansættelse (salg/bogført værdi)-data
| Pris til omsætning | 13025.33 |
| Pris til egenkapital | 0.40 |
| EV i forhold til salg | 4998.33 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
ØKONOMI
Pr. aktie
Loading...
Data pr. aktie
| Aktuelt antal aktier | 46.23M |
| EPS (TTM) | -2.58 |
| FCF pr. aktie (TTM) | -2.09 |
Resultatopgørelse
Loading...
Resultatopgørelse-data
| Omsætning (TTM) | 17.00K |
| Bruttofortjeneste (TTM) | -7.44M |
| Driftsindkomst (TTM) | -168.38M |
| Nettoindkomst (TTM) | -143.48M |
| EPS (TTM) | -2.58 |
| EPS (1 år frem) | -3.61 |
Marginer
Loading...
Marginer-data
| Bruttomargin (TTM) | -43747.06% |
| Driftsmargin (TTM) | -214748.36% |
| Fortjenstmargin (TTM) | -214748.36% |
Balance
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Balancedata
| Kontanter | 187.54M |
| Nettotilgodehavender | 0.00 |
| Omsætningsaktiver i alt | 510.76M |
| Goodwill | 0.00 |
| Immaterielle aktiver | 0.00 |
| Ejendomme, anlæg og udstyr | 0.00 |
| Sum aktiver | 604.03M |
| Kreditor | 2.92M |
| Kortfristet/nuværende langsigtet gæld | 24.83M |
| Summen af kortfristede forpligtelser | 29.46M |
| Sum gæld | 51.08M |
| Aktionærernes egenkapital | 552.95M |
| Materielle nettoaktiver | 0.00 |
Likviditet
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Kontantstrøm-data
| Likviditet fra driften (TTM) | -113.37M |
| Investeringsudgifter (TTM) | 2.67M |
| Fri pengestrøm (TTM) | -116.04M |
| Udbetalt udbytte (TTM) | 0.00 |
Finansiel indkomst
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Data om finansiel indkomst
| Egenkapitalafkast | -25.95% |
| Afkast af aktiver | -23.75% |
| Afkast af investeret kapital | -25.71% |
| Kontant afkast af investeret kapital | -20.79% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
INFORMATION OM AKTIER
Aktiediagram
Loading...
Aktiekurs-data
| Åbning | 4.42 |
| Daglig høj | 4.83 |
| Daglig lav | 4.38 |
| Daglig volumen | 720K |
| Højeste gennem alle tider | 52.67 |
| 1 års analytiker estimat | 45.64 |
| Beta | 2.80 |
| EPS (TTM) | -2.58 |
| Udbytte pr. aktie | - |
| Ex-div dato | - |
| Næste dato for resultatpræsentation | - |
Nedsidepotensial
Loading...
Nedsidepotensial-data
| FDMT | S&P500 | |
| Nuværende prisfald fra top notering | -90.91% | -2.16% |
| Højeste prisfald | -95.23% | -56.47% |
| Højeste efterår dato | 8 Apr 2025 | 9 Mar 2009 |
| Gennemsnitlig fald fra toppen | -64.10% | -11.05% |
| Gennemsnitlig tid til nyt højdepunkt | 161 days | 12 days |
| Maks. tid til nyt højdepunkt | 1086 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
OPLYSNINGER OM VIRKSOMHEDEN
Markedsværdi
221.43M
Markedsværdi kategori
Small-cap
Beskrivelse
4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.
Personale
147
Hjemmeside
Investor relationer
-
SEC-indsendelser
Adm. direktør
Land
USA
By
Aktietype
-
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRÆSENTATIONER
ArrangementerPræsentationer
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FORSTÅ FORRETNINGEN
Loading...
NYHEDER OM VIRKSOMHEDEN
Seeking AlphaPressemeddelelser
iO Charts is a Seeking Alpha partnerNæste side